{"celex_id": "31993D0590", "uri": "http://publications.europa.eu/resource/cellar/6150622d-5944-4bf9-9dec-7cb56cab71c7", "type": "Decision", "concepts": ["1598", "2218", "3660", "4281", "4635", "994"], "title": "93/590/EC: Commission Decision of 5 November 1993 for the purchase by the Community of foot-and-mouth disease antigens within the framework of the Community action concerning reserves of foot-and-mouth disease vaccines\n", "header": "COMMISSION DECISION of 5 November 1993 for the purchase by the Community of foot-and-mouth disease antigens within the framework of the Community action concerning reserves of foot-and-mouth disease vaccines\n(93/590/EC)THE COMMISSION OF  THE EUROPEAN COMMUNITIES", "recitals": ",\nHaving regard to the Treaty establishing the European Community,\nHaving regard to Council Decision 90/424/EEC of 26 June 1990 on expenditure in the veterinary field (1), as last amended by Commission Decision 93/439/EEC (2), and in particular Article 14 thereof,\nHaving regard to Council Decision 91/666/EEC of 11 December 1991 establishing Community reserves of foot-and-mouth disease vaccines (3), and, in particular, Articles 5 and 7 thereof,\nWhereas, in conformity with Decision 91/666/EEC, the purchase of antigens is a part of the Community action to establish Community reserves of foot and mouth disease vaccines;\nWhereas the Commission has issued a call for tenders for the supply of antigens;\nWhereas the Commission has examined the submitted tenders taking into account the following factors:\n- the technical requirements of Annex II to Decision 91/666/EEC and other criteria mentioned in Article 5 of that Decision,\n- that some establishments are unable to supply the full number of doses of some antigens,\n- the need for the producing establishment to be in full conformity with the guidelines for good manufacturing practices (GMP);\nWhereas the Commission has selected Rh\u00f4ne-M\u00e9rieux to supply five million doses of each of subtypes A5, A22, O1 European strain and O1 Middle East strain as a first step; whereas the establishments which will supply the other strains in Annex I to  Decision 91/666/EEC will be decided after a further call for tenders;\nWhereas financial provisions should be made to allow the Commission to purchase these strains from Rh\u00f4ne-M\u00e9rieux;\nWhereas, under the provisions of Article 7 of Decision 91/666/EEC, it is necessary to lay down the rules for the distribution of antigen reserves between the antigen banks, nominated in Article 1 of the said Decision;\nWhereas it is appropriate that each strain should be divided equally between two banks; whereas the strains stored in each bank should be related geographically to the most likely area of risk;\nWhereas in accordance with Article 40 of Council Decision 90/424/EEC, checks provided for in Articles 8 and 9 of Council Regulation (EEC) No 729/70 of 21 April 1970 concerning the financing of the common agricultural policy (4) shall apply; whereas,  moreover, certain particular provisions should be made;\nWhereas the measures provided for in this Decision are in accordance with the opinion of the Standing Veterinary Committee,", "main_body": ["1. The Community shall purchase five million doses of each of the following strains of foot-and-mouth disease antigen:\n- A5 European,\n- A22 Middle East,\n- O1 Middle East,\n- O1 European,\nup to a maximum cost of ECU 4 065 million.\n2. The antigen mentioned in paragraph 1 shall be supplied by Rh\u00f4ne-M\u00e9rieux, Pirbright Laboratory, Ash Road, Surrey, United Kingdom.", "1. To meet the objectives of Article 1, the Commission shall conclude a contract, in the name of the European Community, with Rh\u00f4ne-M\u00e9rieux.\n2. The Director General of Directorate General for Agriculture shall be authorized to sign the contract on behalf of the Commission of the European Communities.\n3. Payment to Rh\u00f4ne-M\u00e9rieux shall be made in accordance with the terms of the contract provided for in paragraph 1.", "The antigen shall be divided between the four antigen banks as follows:\n(a) Bayer, Cologne and the Institute for Animal health, Pirbright: 2,5 million doses of each of O1 European strain and A5 in each bank;\n(b) LNPB, Lyon and 1ZP, Brescia: 2,5 million doses of each of O1 Middle East strain and A22 in each bank.", "This Decision is addressed to the Member States."], "attachments": "Done at Brussels, 5 November 1993.\nFor the Commission\nRen\u00e9 STEICHEN\nMember of the Commission\n(1) OJ No L 224, 18. 8. 1990, p. 19.\n(2) OJ No L 203, 13. 8. 1993, p. 34.\n(3) OJ No L 368, 31. 12. 1991, p. 21.\n(4) OJ No L 94, 28. 4. 1970, p. 13."}